Recent advances in developing specific therapies for haemophilia

Abstract excerpt

Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of current replacement therapy is the short half-life of factors VIII and IX. These half-lives have been extended by the addition of various moieties, allowing less frequent infusion regimens. Entirely novel approaches have also entered the clinic, including a bispecific antibody that mimics factor VIII and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood Coagulation and Thrombosis Mechanisms
• Share to Hemophilia Treatment and Research
• Share to Monoclonal and Polyclonal Antibodies Research